| Combination of | |
|---|---|
| Isosorbide dinitrate | Vasodilator |
| Hydralazine | Antihypertensive |
| Clinical data | |
| Trade names | Bidil |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| ChemSpider | |
| KEGG | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify) | |
 | The examples and perspective in this article may not represent a worldwide view of the subject. (May 2016) |
Hydralazine/isosorbide dinitrate, sold under the brand name Bidil, is a fixed-dose combination medication used to treat self-identified Black people with congestive heart failure.[1] It is a combination of hydralazine hydrochloride (an arteriolar vasodilator) and isosorbide dinitrate (a nitrate vasodilator).[1][2]
The American Food and Drug Administration (FDA) approved this race-specific medication to treat congestive heart failure in specifically self-identified Black patients. It provoked controversy as the first drug approved by the FDA marketed for a single racial-ethnic group.[3]
- ^ a b c "Bidil- hydralazine hydrochloride and isosorbide dinitrate tablet, film coated". DailyMed. U.S. National Library of Medicine. 26 January 2021. Retrieved 11 April 2022.
- ^ Ferdinand KC, Elkayam U, Mancini D, Ofili E, Piña I, Anand I, et al. (July 2014). "Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial". The American Journal of Cardiology. 114 (1): 151–159. doi:10.1016/j.amjcard.2014.04.018. PMID 24846808.
- ^ Whitmarsh I, Jones DS, eds. (2010). "Governance and the Uses of Race" (PDF). What's the Use of Race?: Modern Governance and the Biology of Difference. Cambridge, MA: MIT Press. ISBN 978-0-262-51424-8. Archived from the original (PDF) on 5 March 2016. Retrieved 8 December 2013.* Panizzo R (21 November 2011). "Book Review: What's the Use of Race? Modern Governance and the Biology of Difference". BioNews. No. 634.